Clinical Evaluation of Grindelia robusta in Recurrent Acute Bronchitis: An Observational Study

Abstract

Grindelia robusta is described in homoeopathic literature as having a marked affinity for the bronchial mucosa, especially in cases characterized by viscid expectoration and positional dyspnea. Systematic clinical documentation is required to substantiate its therapeutic utility. Aim of this study was to evaluate the clinical effectiveness of Grindelia robusta in pediatric patients suffering from recurrent acute bronchitis. This is a prospective, single-arm observational study was conducted in children aged 5–15 years 30 cases diagnosed with recurrent acute bronchitis. Individualized prescription of Grindelia robusta (6C) was made based on totality of symptoms. Outcome measures included Bronchitis Severity Score (BSS), cough frequency, expectoration characteristics, pain while coughing, rales on auscultation and dyspnea grading. Statistical analysis was performed using paired t-test. The mean BSS significantly reduced from 7.82 ± 1.14 at baseline to 3.08 ± 1.02 post-intervention (p < 0.001). Marked improvement was observed in 68% of participants, while 22% showed moderate improvement. No adverse drug reactions were reported. Grindelia robusta demonstrated statistically significant clinical improvement in recurrent acute bronchitis. Controlled randomized studies are warranted to further validate these findings.